ClinTec International is pleased to announce the appointment of Dr Robert Reekie as Chief Operating Officer (COO) and Senior Executive Vice President, as it continues to demonstrate strong growth and international expansion.
Following the recent appointment of Dr Harley Simon, as Chief Medical Officer (CMO) and Executive Vice President (EVP) Client Relations, we introduce Dr Reekie, who brings with him 30 years of drug development expertise and experience in successfully commercializing a wide range of drug development services.
The CEO and founder of ClinTec International, Dr Rabinder Buttar, said: “As our company enters its 20th year of significant organic growth, Dr Reekie represents a further strengthening and expansion of our Senior Executive leadership team. Dr Reekie brings three decades of experience, during which he has grown a CRO into a top 10 global player. Dr Reekie will support our senior team in guiding ClinTec through further significant expansion, during which we will retain a major focus on meeting the needs of our clients. He will steer the governance, operational delivery and further development of two major new preferred provider partnerships with leading pharmaceutical organizations. For one of these we are chosen as a full-service late phase clinical research partner for Europe and for the second one, a full-service global clinical programme development partner.”
Dr Reekie said: “I have followed the impressive international expansion of ClinTec for some time and I am delighted to be joining ClinTec at this exciting time for the organization and, especially, to continue the delivery of operational excellence to both our new partner companies and to existing clients.”
Dr Reekie was previously COO of the Phase II-IV division at the large global contract research organization, inVentiv Health Clinical, and COO at its predecessor, PharmaNet Inc., ultimately responsible for operational delivery through an organization of 2500 staff based in more than 40 countries.
His operational leadership supported significant geographical expansion into Eastern Europe and Asia and the effective governance of new client relationships, in addition to restructuring and integration following acquisition activity and changes in ownership. He served on the senior global executive committee, in Princeton, New Jersey, and is also on several local boards of directors, based throughout Europe and Asia.
He has also recently served as Commercial Director at Stratified Medicine Scotland-Innovation Centre and as non-executive director representing investors on the boards of a Phase I clinical service company and a specialized contract manufacturing company. Previously head of several clinical development groups in Boots Pharmaceuticals, he led clinical product development across a number of therapeutic areas and joined the pharmaceutical services sector in 1995 as Medical Director to DAR Ltd., subsequently at ClinTrials Research, as Director of Medical & Regulatory Affairs and then as Senior Director Business & Regional Operations.
He holds a BSc from St Andrews University, an MB ChB from the University of Edinburgh and an MBA from the University of Nottingham School of Management and Finance. A medical practitioner registered in the UK, and initially working in medical practice in Scotland, he is also a Fellow of the Faculty of Pharmaceutical Medicine (UK Royal Colleges of Physicians).